BioCision and Cook Ink Deal

BioCision LLC has entered into an exclusive partnership with Cook Regentec to develop two custom CoolCell controlled-rate cell freezing systems for Cook’s closed-system cell therapy CellSeal vials.

Cook selected BioCision’s proprietary CoolCell technology for its effectiveness in standardizing the freezing of cells and cellular therapies such as stem cells and tissue samples that can be used in a wide range of applications from diabetes research to organ transplants. The company said the ease of implementation and use of CoolCell freezing systems will provide Cook’s CellSeal vial customers a cost-effective, reliable solution for controlled -1 degree Celsius per minute cell freezing, the rate believed to be optimal to ensuring cells remain intact and experience minimal negative effects during the freezing process.

“Our CoolCell technology platform is ideal for customization into emerging formats, such as the CellSeal closed-system vial,” said Rolf Ehrhardt, chief executive officer, BioCision. “This partnership with Cook Regentec, a leader in the field of cell therapy, will enable users of these vials to standardize the cryopreservation of their cell therapy products. This is an important step forward for the industry and, most importantly, for the patients who rely on precise handling of these sensitive materials.”

This agreement encompasses the development of two customized cell freezing CoolCell systems for Cook’s CellSeal vials, as well as the adaptation of other BioCision technology platforms to this format, and is the latest in a series of customized products BioCision has developed for the cell therapy industry.